[go: up one dir, main page]

AR102248A1 - Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes - Google Patents

Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes

Info

Publication number
AR102248A1
AR102248A1 ARP150103296A ARP150103296A AR102248A1 AR 102248 A1 AR102248 A1 AR 102248A1 AR P150103296 A ARP150103296 A AR P150103296A AR P150103296 A ARP150103296 A AR P150103296A AR 102248 A1 AR102248 A1 AR 102248A1
Authority
AR
Argentina
Prior art keywords
diabetes
prevention
treatment
pharmaceutical compositions
aromatic compounds
Prior art date
Application number
ARP150103296A
Other languages
English (en)
Inventor
Grouix Brigitte
Gagnon Lyne
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of AR102248A1 publication Critical patent/AR102248A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de compuestos para prevenir y/o tratar diabetes, para modular los niveles de glucosa insulina y/o triglicéridos; para reducir el nivel de glucosa en sangre para mantener o aumentar el nivel de insulina para aumentar la secreción; aumentar la sensibilidad a la insulina o disminuir la resistencia a la insulina en un sujeto. Reivindicación 8: El método de cualquiera de las reivindicaciones de 1 a 7 caracterizado por que dicho compuesto se representa por una de las estructuras del grupo de fórmulas (1); o una sal farmacéuticamente aceptable de este.
ARP150103296A 2014-10-10 2015-10-13 Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes AR102248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062526P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
AR102248A1 true AR102248A1 (es) 2017-02-15

Family

ID=55652427

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103296A AR102248A1 (es) 2014-10-10 2015-10-13 Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes

Country Status (21)

Country Link
US (1) US10105331B2 (es)
EP (1) EP3203998B1 (es)
JP (1) JP6676629B2 (es)
KR (1) KR20170066614A (es)
CN (1) CN106999458B (es)
AR (1) AR102248A1 (es)
AU (1) AU2015330643B2 (es)
BR (1) BR112017007420A2 (es)
CA (1) CA2963276A1 (es)
DK (1) DK3203998T3 (es)
ES (1) ES2875336T3 (es)
IL (1) IL251392B (es)
MX (1) MX376872B (es)
PH (1) PH12017500662B1 (es)
PL (1) PL3203998T3 (es)
PT (1) PT3203998T (es)
RU (1) RU2723486C2 (es)
SG (1) SG11201702812PA (es)
TW (1) TWI699201B (es)
UY (1) UY36354A (es)
WO (1) WO2016054726A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2723486C2 (ru) * 2014-10-10 2020-06-11 Прометик Фарма Смт Лимитед Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета
RU2728782C2 (ru) * 2014-11-12 2020-07-31 Лиминал Байосайенсиз Лимитед Замещенные ароматические соединения и фармацевтические композиции для ауторепарации и регенерации ткани
BR112021006907A2 (pt) 2018-10-11 2021-09-08 Basf As Compostos aromáticos e usos farmacêuticos destes
CN116568291A (zh) * 2020-10-06 2023-08-08 殷格纽制药有限公司 取代的芳香族化合物及其药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP4697962B2 (ja) * 2003-02-13 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝性障害の処置のための化合物
AU2005284798B2 (en) * 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
JP2012072136A (ja) * 2010-09-03 2012-04-12 Erina Co Inc 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
AU2011356584B2 (en) * 2010-10-27 2016-03-10 Liminal Biosciences Limited Compounds and pharmaceutical compositions for uses in diabetes
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
RU2723486C2 (ru) * 2014-10-10 2020-06-11 Прометик Фарма Смт Лимитед Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета

Also Published As

Publication number Publication date
US10105331B2 (en) 2018-10-23
TW201618763A (zh) 2016-06-01
RU2017116106A (ru) 2018-11-12
CA2963276A1 (en) 2016-04-14
JP6676629B2 (ja) 2020-04-08
MX2017004738A (es) 2017-08-10
TWI699201B (zh) 2020-07-21
CN106999458B (zh) 2021-04-13
IL251392A0 (en) 2017-05-29
KR20170066614A (ko) 2017-06-14
PL3203998T3 (pl) 2021-09-27
EP3203998A1 (en) 2017-08-16
EP3203998B1 (en) 2021-03-10
BR112017007420A2 (pt) 2018-01-16
DK3203998T3 (da) 2021-05-31
AU2015330643B2 (en) 2020-05-14
SG11201702812PA (en) 2017-05-30
CN106999458A (zh) 2017-08-01
WO2016054726A1 (en) 2016-04-14
MX376872B (es) 2025-03-07
US20170209399A1 (en) 2017-07-27
AU2015330643A1 (en) 2017-05-04
RU2017116106A3 (es) 2019-02-13
ES2875336T3 (es) 2021-11-10
PT3203998T (pt) 2021-06-07
UY36354A (es) 2016-06-01
RU2723486C2 (ru) 2020-06-11
PH12017500662A1 (en) 2017-10-02
EP3203998A4 (en) 2018-06-20
PH12017500662B1 (en) 2022-08-19
JP2017530182A (ja) 2017-10-12
IL251392B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
UY37363A (es) Sulfonilureas y compuestos relacionados y sus usos
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
EP3895717C0 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2015003442A1 (es) Derivados heterociclicos
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2021000329A1 (es) Compuestos útiles en terapia del vih
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS

Legal Events

Date Code Title Description
FB Suspension of granting procedure